Overview of Normorytmin

Property	Description
Active ingredient	Propafenone hydrochloride
Form	Tablets (film-coated) and solution for injection
Pharmacological class	Vaughan Williams Class Ic Antiarrhythmic Agent
Common purpose	Restoring and maintaining a normal heart rhythm
Origin	Synthetic compound

Normorytmin is a synthetic, prescription-only medication whose active ingredient is Propafenone hydrochloride, a compound derived from the propanolamine chemical structure. It is formally designated as an antiarrhythmic drug, and more specifically, classified under the Vaughan Williams system as a Class Ic agent, indicating its intensive action on the heart’s electrical system. This classification is clinically recognized for drugs primarily functioning via the blockade of cardiac sodium channels. This preparation is a single-component product of synthetic origin, providing a focused electrical stabilization effect, distinguishing it from antiarrhythmics that possess a multi-channel blockade profile. The compound's chemical structure is C21H27NO3.

Primary Function and Available Preparations

The general function of Normorytmin is to restore and maintain a more regular and controlled heartbeat by providing direct electrical stabilization to the cardiac conduction system. Its primary utility is observed in situations where the heart is experiencing an unstable rhythm. The medication works by producing a membrane-stabilizing action on myocardial tissue. This specific mechanism helps suppress the rapid, chaotic electrical impulses that can destabilize cardiac timing. For therapeutic use, the medicine is available for systemic administration in two dosage form(s): film-coated tablets for oral ingestion, typically used for long-term maintenance, and a solution for injection for intravenous (parenteral) delivery, which is employed in acute settings demanding a rapid clinical response.

Regulatory References

Vaughan-Williams Classification of Antiarrhythmic Drugs

What side effects are possible with Normorytmin?

Possible Side Effects and Safety Information

Propafenone hydrochloride (Normorytmin) has a safety profile defined by regulatory bodies, including the FDA and the EMA, detailing potential adverse reactions classified by frequency and affected body system. The most significant safety concern is the potential for proarrhythmic effects—the risk of causing new or worsening heart rhythm disorders, which can be life-threatening and is a key safety consideration for this class of medicine.

Adverse Reactions by Official Frequency

Adverse reactions are grouped according to their occurrence rate documented in official labeling:

Very Common (Affecting ge1 in 10 patients): Dizziness, cardiac conduction disorders (e.g., first-degree AV block), and palpitations.
Common (Affecting ge1 in 100 to <1 in 10 patients): Gastrointestinal issues (such as nausea, vomiting, constipation, dry mouth), anxiety, headache, and taste disturbance (metallic or bitter taste).
Uncommon: Reactions such as insomnia, syncope (fainting), and bradycardia (slow heart rate) are documented.
Not Known: This category includes rare, post-marketing events, such as agranulocytosis (a severe decrease in white blood cells) and hepatitis, which cannot be reliably estimated from available data.

Regulatory Safety Limitations

Official regulatory documents mandate strict limitations on the use of Normorytmin due to safety risks. The medication is contraindicated in individuals with structural heart disease, severe heart failure, or cardiogenic shock, given the significantly increased risk of serious adverse events, including proarrhythmia and sudden death. It is also restricted for use in patients with Brugada syndrome, marked hypotension (low blood pressure), or severe uncompensated cardiac conduction disorders.

Population-Specific Safety Notes

Caution is advised by regulatory agencies when using propafenone in patients with pre-existing hepatic or renal impairment because drug accumulation may occur. Furthermore, the label notes that the medication may affect the sensing and pacing thresholds of permanent pacemakers, which may require monitoring and adjustment of the device.

Overdose and Emergency Response

Overdose and when to seek help

Normorytmin (Propafenone hydrochloride) overdose is officially documented as a severe and potentially life-threatening event requiring immediate medical intervention. The primary manifestations of overdose reflect the drug's potent antiarrhythmic class, involving serious electrical and hemodynamic disturbances. These include severe conduction disorders such as QRS widening, AV block, and PQ prolongation, often accompanied by hypotension. Severe toxicity can rapidly escalate to ventricular fibrillation, profound myocardial depression, and cardiac arrest. Central nervous system effects, including convulsions, have also been reported.

Immediate medical attention must be sought for any suspected overdose. Management is strictly symptomatic and supportive, as the official regulatory labeling confirms that no specific antidote is known. While standard elimination procedures like haemodialysis are unlikely to succeed, prompt use of gastric lavage is described as a measure to eliminate excessive doses. Close monitoring for signs of overdosage is essential for patients with impaired liver or kidney function, due to the increased risk of drug accumulation.

Therapeutic Uses of Normorytmin

What Normorytmin Treats: Main Uses and Benefits

Normorytmin is an approved therapeutic intervention used to address symptoms in individuals experiencing specific types of cardiac arrhythmias. It is indicated for the management of heart rhythm disorders that originate both above the ventricles, such as atrial fibrillation and atrial flutter, and certain rhythm disturbances within the ventricles, including recurrent ventricular tachycardia.

This medication’s role is to support the maintenance of a stable, consistent heart rhythm, which may help alleviate associated symptoms. The benefit to the patient is focused on improving the management of their heart rate and rhythm stability. Clinical use of this compound is centered on these specific cardiovascular indications.

Quick Fact: Relief for Irregular Heartbeat Normorytmin is designed to support the stabilization of the heart’s electrical activity to modulate episodes of rapid or irregular rhythm.

Eligibility and Restrictions for Use

Who Can and Cannot Use Normorytmin?

The population eligibility for Normorytmin (Propafenone hydrochloride) is strictly defined by regulatory documents, primarily focusing on cardiac status and organ function.

Contraindicated Populations (Absolute Non-Eligibility)

The medicine is strictly contraindicated and must not be used by individuals with certain severe pre-existing conditions, as defined in official labeling. These include uncontrolled congestive heart failure, cardiogenic shock, and Known Brugada Syndrome. It is also prohibited for patients with most cardiac conduction disorders (such as Sick Sinus Syndrome or AV block) unless a permanent artificial pacemaker is present. Additional contraindications include marked hypotension and severe obstructive pulmonary disease.

Restricted and Age-Related Use

Population Group	Regulatory Status
Pediatric Population (<18)	Use is not established and not recommended; appropriate safety studies have not been performed.
Severe Hepatic Impairment	Requires extreme caution and often mandates a significant dose reduction due to altered metabolism.
Pregnancy/Lactation	Conditional use only if the potential benefit to the mother formally outweighs the potential risk to the fetus or infant.

Eligibility also requires the absence of marked electrolyte imbalance and generally excludes patients with structural heart disease or recent myocardial infarction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The activity of Normorytmin can be significantly affected by other medicines, which may alter the concentration of Normorytmin in the body or enhance its effects on the heart.

Normorytmin is primarily metabolized by liver enzymes, notably Cytochrome P450 3A4 (CYP3A4) and CYP2D6. Medicines that strongly inhibit CYP3A4, such as certain antifungal agents (e.g., ketoconazole) or antiarrhythmics (e.g., amiodarone), can increase the amount of Normorytmin in the bloodstream, raising the potential for serious effects. Conversely, strong enzyme inducers (e.g., rifampicin) can decrease Normorytmin levels, potentially reducing its effectiveness.

Product Category	Interaction Summary
Other Antiarrhythmics (Class I)	Concomitant use is generally not recommended due to an increased risk of severe adverse cardiac events.
QT-Prolonging Medicines	Combination with other medicines known to prolong the QTc interval (e.g., specific antipsychotics, macrolide antibiotics) is restricted due to a risk of serious ventricular rhythm disturbances like Torsade de Pointes.
Blood Thinners (e.g., Warfarin)	Normorytmin may increase the plasma concentration of these agents, necessitating dose adjustments and careful monitoring of bleeding risk.

Additionally, Normorytmin itself acts as an inhibitor of CYP2D6, which may increase the blood levels of other medicines that are metabolized by this enzyme (e.g., certain antidepressants or beta-blockers). Grapefruit juice can also increase the concentration of Normorytmin and should be avoided.

Mechanism of Action

Normorytmin acts as an allosteric inhibitor of the serine/threonine protein kinase mTOR (mechanistic Target of Rapamycin) within the mTOR Complex 1 (mTORC1). The molecule first binds with high affinity to the intracellular receptor protein FKBP12 (FK506-binding protein 1A) to form a drug-protein complex.

This resulting complex, Normorytmin-FKBP12, then interacts directly with the FKBP12-rapamycin-binding (FRB) domain of the mTOR kinase subunit in mTORC1. This interaction prevents the essential conformational change required for Raptor-mediated substrate recruitment and catalytic activation. The resulting inhibition of mTORC1 activity reduces the phosphorylation of downstream effector proteins, specifically S6K1 (p70 ribosomal S6 kinase) and 4E-BP1 (eukaryotic translation initiation factor 4E-binding protein 1). Consequently, this molecular block decreases the rate of ribosomal biogenesis and protein synthesis and suppresses the catabolic process of autophagy. The system-level physiological consequence is the modulation of cellular proliferation, differentiation, and overall cell cycle progression, primarily in tissues with high metabolic activity.

Dosage and Administration Information

How to Use Normorytmin

Normorytmin (propafenone hydrochloride) is administered through oral or intravenous routes, with the chosen method depending on the clinical context and formulation. The oral form is available as immediate-release (IR) tablets and extended-release (ER) capsules.

Initial treatment with the oral form is typically managed under hospital conditions by a specialist, involving continuous monitoring of the heart’s electrical activity and blood pressure. This supervised initiation phase is necessary to establish the individually appropriate regimen.

Official Dosing Patterns

The treatment schedule is structured as a stepped titration process with defined intervals for dose adjustments:

Formulation	Starting Dose	Maximum Daily Dose	Frequency
IR Tablets	150 mg three times daily (TID)	Not to exceed 900 mg	Three times daily (q8hr)
ER Capsules	225 mg twice daily (BID)	Not to exceed 850 mg	Twice daily (q12hr)

Administration Requirements and Adjustments

For IR tablets, the dose is generally taken after food to enhance absorption. ER capsules must be swallowed whole and must not be crushed, chewed, or divided. Dose increases for IR tablets may occur after a minimum of 3 to 4 days, while ER capsules require a minimum of 5-day intervals between titrations.

Specific adjustments are mandated for certain patient groups. Treatment in older adults should begin cautiously with smaller incremental doses. Patients with hepatic impairment require a significant reduction in the starting and maintenance dose due to the risk of drug accumulation. If an oral dose is missed, patients should only take the next scheduled dose; they must not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Normorytmin

Evidence for Use in Atrial Fibrillation and Atrial Flutter

The research base for Normorytmin (Propafenone) in the management of upper-chamber rhythm problems, such as Atrial Fibrillation and Atrial Flutter, primarily consists of Randomized Controlled Trials (RCTs) and meta-analyses. These studies explored whether rhythm restoration and stability could be observed over time. Researchers examined how the heart’s electrical activity changes during an irregular episode and measured the rate and time interval associated with recording a normal sinus rhythm. This evidence generally involves individuals with recurrent, symptomatic episodes. However, the results apply only to the populations studied, as most key trials excluded patients with pre-existing structural heart disease—such as severe heart failure—concentrating on those whose primary issue was the electrical rhythm disturbance alone.

Evidence for Use in Documented Ventricular Arrhythmias

The research on Normorytmin for rhythm disturbances originating in the heart's lower chambers (ventricles) was evaluated in controlled clinical trials. These studies were typically short-term, focusing on immediate changes. Researchers examined studies exploring the heart’s abnormal electrical activity, monitoring the reduction in the frequency of specific irregular beats. The evidence base has primarily focused on patients with more severe, life-threatening ventricular arrhythmias. Regulatory evaluations noted that the drug could potentially cause a new or worsening arrhythmia (proarrhythmia) in certain individuals, particularly those with structural heart disease.

Research Gaps and Uncertainties

Certainty remains low in several key areas. The major research gap is the limited controlled trial evidence available to evaluate whether the use of Normorytmin is associated with improved long-term outcomes, such as overall survival or the incidence of sudden cardiac death. Additionally, follow-up durations were limited in many studies. Data for certain groups remain insufficient, including patients with significant structural heart disease and specific populations like pediatric or older adult patients.

Key Studies & References Efficacy and Safety of Propafenone for Conversion and Maintenance of Sinus Rhythm in Atrial Fibrillation: A Systematic Review and Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Normorytmin (FAQ)

Q: Does Normorytmin interact with grapefruit?

Official product information notes that grapefruit juice can interact with Normorytmin. The components in grapefruit juice can inhibit a specific liver enzyme that is used to process the medicine. Because of this interference, the concentration of Normorytmin in the bloodstream could increase, raising the potential for serious effects.

Q: Are there any specific foods I should avoid when taking Normorytmin?

The only specific food interaction mentioned in official regulatory documents is the recommendation to avoid grapefruit juice due to its potential to increase the drug's concentration in the body. Beyond that, the prescribing instructions generally state that immediate-release tablets are usually taken after food, but no other food restrictions are typically highlighted.

Q: Can Normorytmin interact with alcohol?

While official prescribing information does not specifically forbid alcohol consumption, it is noted that side effects can include dizziness and other central nervous system (CNS) disturbances. Combining the medication with alcohol could potentially worsen these effects.

Q: Can Normorytmin interact with herbal supplements?

Regulatory documents include a general warning about taking the drug with strong inhibitors of CYP enzymes (liver enzymes). This is the mechanism of interaction for many other substances, including some herbal and botanical supplements. Information should be checked for any product that may affect the liver enzymes.

Q: Can Normorytmin be taken with antacids?

Official labeling addresses interactions with certain antacids, specifically those containing famotidine. Taking Normorytmin alongside certain antacids could potentially increase the risk of an irregular heart rhythm (proarrhythmia). This information comes from the drug's interaction profile.

Q: Is Normorytmin safe for older adults to use?

Regulatory documents advise that treatment for older adults should begin with caution. This often means starting with smaller incremental doses due to potential differences in how older bodies metabolize the medicine. This approach is intended to manage the risk of drug accumulation.

Q: What is the research status on Normorytmin for pediatric use?

Official documents consistently state that the safety and effectiveness of Normorytmin for patients under 18 years of age have not been established. For this reason, use in the pediatric population is generally not recommended.

Q: Is Normorytmin a controlled substance?

According to regulatory sources, including the US Drug Enforcement Administration (DEA), Normorytmin (propafenone hydrochloride) is not listed as a controlled substance.

Q: What is the difference between Normorytmin and [Similar Drug X]?

Normorytmin is formally classified under the Vaughan Williams system as a Class Ic Antiarrhythmic Agent. This classification is based on its primary mechanism of action: its intensive effect on the heart's electrical system, which differentiates it from other classes of heart rhythm medications.

Q: Is it common to feel tired when first starting Normorytmin?

Regulatory documents list fatigue as a Common adverse reaction in the official safety profile. This means it is among the side effects reported to affect between 1 in 10 and 1 in 100 patients.

Q: Can Normorytmin cause trouble sleeping?

Trouble sleeping, or Insomnia, is listed as an Uncommon adverse reaction in the official safety profile of the medication. This means it is among the side effects reported to affect between 1 in 100 and 1 in 1,000 patients.

Q: Does Normorytmin cause any changes in mood?

Anxiety is explicitly listed as a Common adverse reaction in the official safety profile. This indicates that some patients may experience feelings of anxiety while taking the drug.

Q: Can Normorytmin affect my blood pressure?

Official labeling lists marked hypotension (severe low blood pressure) as a contraindication for use. The drug may also influence the cardiovascular system, which can affect blood pressure. During initial treatment, monitoring of blood pressure is recommended.

Q: How long will I likely need to stay on Normorytmin?

The medication is indicated to prolong the time to recurrence of symptomatic arrhythmias, suggesting it is often used for long-term maintenance therapy in eligible patients. The specific duration of use is determined by clinical factors and is not standardized in regulatory documents.

Q: Is Normorytmin used for prevention or just for active problems?

According to its official indications for use, Normorytmin is prescribed to prolong the time to recurrence of symptomatic atrial fibrillation. This is generally considered a form of maintenance therapy or secondary prevention to keep the heart rhythm stable after an event.

Q: Do I need any special monitoring tests while on Normorytmin?

Regulatory documents recommend that patients be evaluated electrocardiographically (ECG) and clinically both before and during therapy. Furthermore, if a patient has a permanent pacemaker, its function must also be monitored during treatment.

Q: Does Normorytmin affect potassium or sodium levels?

Official warnings state that the medicine is contraindicated in patients with a marked electrolyte imbalance. Specifically, low levels of potassium (hypokalemia) or magnesium can reduce the drug's effectiveness and increase potential risks.

Q: What happens if I accidentally take two doses of Normorytmin?

The product label includes an Overdose section that describes the potential symptoms of toxicity associated with high doses. These symptoms can include slow heart rate, low blood pressure, and in severe cases, seizures. If an accidental overdose is suspected, it is described as necessary to seek prompt medical care.

Q: Can Normorytmin affect my ability to drive or operate machinery?

Side effects such as dizziness (Very Common) and blurred vision (Uncommon) are noted in the official safety profile. These effects may potentially impair the ability to drive or operate machinery, and caution is advised.

Q: What kind of studies support the use of Normorytmin?

The research base described in official documents consists primarily of Randomized Controlled Trials (RCTs) and controlled clinical trials. These studies focus on the drug’s effectiveness for rhythm restoration and stability in eligible patient populations.

Q: What is the general expectation for improvement when starting Normorytmin?

The expectation described in official documents is the restoration and maintenance of normal sinus rhythm or the prolonging of the time to recurrence of the arrhythmia. These measures are used to assess the drug’s efficacy in symptomatic patients.

Q: What should I do if a minor side effect from Normorytmin doesn't go away?

Official labeling directs that adverse reactions should be reported to the prescriber. It is noted that some non-severe side effects may diminish as the body adjusts to the medicine, but any persistent or concerning symptoms should be discussed with a healthcare provider.

Q: Is it okay to drink coffee while taking Normorytmin?

The official label does not mention coffee. However, the medicine may affect the body’s processing of caffeine, and caution may be warranted.

Q: Can Normorytmin cause dry mouth?

Dry mouth is explicitly listed as a Common adverse reaction in the official safety profile. This means it is among the side effects reported to affect between 1 in 10 and 1 in 100 patients.

How should Normorytmin be stored and disposed of?

To maintain the quality of Normorytmin (propafenone hydrochloride), regulatory bodies specify strict storage and disposal requirements.

Storage Component	Official Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Protect from light, moisture, and do not freeze.
Container Rule	Keep in the original container and ensure it is tightly closed.
Child Safety	Keep out of the sight and reach of children to prevent accidental ingestion.

The solution for injection has an in-use stability limit, requiring the diluted product to be used within a specified period, such as 24 hours. Unused or expired Normorytmin must be disposed of according to local pharmaceutical waste regulations, preferably through a drug take-back program. It is prohibited to dispose of the medicine by flushing it into wastewater (sink or toilet).

Normorytmin